The estimated Net Worth of Ken Keyong Ren is at least $113 mil dollars as of 19 January 2016. Ken Ren owns over 15,000 units of CASI Pharmaceuticals Inc stock worth over $113,250 and over the last 10 years Ken sold CASI stock worth over $0.
Ken has made over 1 trades of the CASI Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Ken bought 15,000 units of CASI stock worth $10,950 on 19 January 2016.
The largest trade Ken's ever made was buying 15,000 units of CASI Pharmaceuticals Inc stock on 19 January 2016 worth over $10,950. On average, Ken trades about 1,364 units every 0 days since 2014. As of 19 January 2016 Ken still owns at least 15,000 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of Ken Ren stock trades at the bottom of the page.
Ken's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE, MD, 20850.
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya, ePharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: